Compare iShares MSCI Singapore ETF (EWS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Novartis AG — how do they compare? iShares MSCI Singapore ETF trades at $33.66, while Novartis AG trades at $152.64 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| EWS | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $33.92 | $168.62 |
52-Week Low | $26.71 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $33.66, up 1.48% today and hitting a new 52-week high. Technical indicators show a bullish moving average consensus but overbought RSI signals. The ETF benefits from Singapore's economic resilience and AI-driven growth momentum, with institutional buying from firms like Amundi. Dividend yield remains attractive at 3.97% with consistent payout history.
Outlook remains positive given Singapore's market reforms and AI infrastructure growth, though concentrated financial sector exposure (54%) poses sector-specific risks. Near-term resistance at $34 may challenge further upside without fundamental catalysts. The ETF offers strategic Asian diversification but requires monitoring of regional economic developments.
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
